Scientists develop an algorithm to measure the risk of Hawaiian cancer

At the age of 36, Natasa Wray had just completed a two-year painful treatment for cancer when doctors warned her of another threat approaching an increased risk of Navajo cancer.

She faced a dilemma that changed her life that subjected her to surgery to remove the ovaries and ovarian tubes, eliminating the risk of Hawaiian cancer, or retaining her fertility and the possibility of having a child.

I was 36 years old at the time and I said absolutely not... I also didn't want to go through a surgical menopause in the mid - 30s”, she says.

I really wanted to be a mother, so I definitely wanted to save every fertility I had”, writes Euronews.

Unlike breast cancer, there is no equivalent of mammography for Iranian cancer, and for women with high genetic risk, such as those that sustain BRCA1 or BRCA2 mutations, preventative surgery remains the most effective way of reducing the risk, although it leaves non-proliferation women.

Wrayt was given the opportunity to enter a pilot test conducted by London University College Hospital.

The blood test is called ROCA, which means “algoritation of the risk of Iranian cancer” and allows doctors to control proteins and other substances that cause cancer, as well as changes in cancer-related genes.

For women like Wray, the test offered security and important time to create a family before considering surgical intervention.

Thanks to the ROCA test, Wray was able to delay surgical surgery enough to give birth to her son.

I was definitely getting enough security from that test to feel safe”, Wray said.

After she was born, her test showed that she had an adult danger.

I think my son was about three years old, we were ready to go on vacation and I remember I was on vacation thinking, okay, the longer I'm going to leave”.

Women at risk are advised to test every four months to monitor any change.

Doctors who conducted the evidence say the test provides “breathing space” for those that are not yet ready for surgery.

The “is actually designed as an option for limiting damage for women who are not yet ready to undergo surgery due to potentially devastating effects that could have surgical intervention on to”, said Adam Rosenthal, a consultant gynecologist at UCLH.

“should not be viewed as an alternative to surgical intervention because they must remove pipes and ovaries at a certain moment”.

It's very individual. Some women will do the test for several months; they may have a slightly abnormal result that is not actually cancer, but it freaks them out, and that's why they go and they undergo operation”, Rosenthal said.

Other “will continue testing because they simply cannot afford the operation until they have passed through a natural menopause. So look at all the extremes and everything between them”, he added.

Now, after a successful test, the test is being made available to high-risk Iranian women in the United Kingdom through National Health Service (NHS), but previously only privately available.

Thousands of women in the United Kingdom who have special genes that put them at a high risk for Iranian cancer have access to the test.

Europe registered the highest rates of incidentity and death of Iranian cancer worldwide in 2020, according to the World Health Organization's International Cancer Research Agency (OBSH). In the same year, approximately 68,000 new cases were reported, according to the European Commission.